Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIO-TECHNE CorpTECH · Entity 3479 | PRESIDENT, PROTEIN SCIENCES | August 17, 2026 | August 19, 2026 |
| Quanterix CorpQTRX · Entity 6649 | Chief Operating Officer | February 08, 2021 | February 10, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIO-TECHNE Corp
Report date August 17, 2026 · Filed August 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 14,762 |
Reported balance
After 2026-08-17 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-08-17 · Grant · Acquired 14,762 · Balance 14,762 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,985 |
Reported balance
After 2026-08-17 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-08-17 · Grant · Acquired 23,985 · Balance 23,985 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11: 23,985 restricted stock units vest on 8/17/2029. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,623 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 2,623 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8: 2,623 restricted stock units vest on 8/15/2027. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,452 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 6,452 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9: 3,226 restricted stock units vest on each of 8/15/2027 and 8/15/2028. |
| Common StockSEC Table I · non-derivative | Direct | 24,943 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 24,943 |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $100.39 · Expires 2029-02-01 | Direct | 15,912 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 15,912 F1: 100% vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $94.52 · Expires 2029-08-15 | Direct | 29,600 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 29,600 F1: 100% vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 1,526 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 1,526 F1: 100% vested. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $84.61 · Expires 2030-08-15 | Direct | 30,059 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 30,059 F2: Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $74.91 · Expires 2034-08-15 | Direct | 21,204 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 21,204 F3: Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $53.60 · Expires 2035-08-15 | Direct | 24,758 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 24,758 F4: Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028. |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 15,738 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 15,738 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
| Performance Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 19,355 |
Reported balance
Holding disclosure · report date 2026-08-17 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 19,355 F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). |
Filing footnotes · ownership attribution and instrument terms
F1: 100% vested.
F2: Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026.
F3: Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
F4: Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028.
F5: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F6: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F7: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: 2,623 restricted stock units vest on 8/15/2027.
F9: 3,226 restricted stock units vest on each of 8/15/2027 and 8/15/2028.
F10: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029.
F11: 23,985 restricted stock units vest on 8/17/2029.
Quanterix Corp
Report date February 08, 2021 · Filed February 10, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,951 |
Reported balance
After 2021-02-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-08 · Grant · Acquired 4,906 · Balance 44,951 F1: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to 25% of the shares on February 8, 2022, and the remaining 75% vest in 36 equal monthly installments at the end of each month beginning on February 28, 2022. F2: Includes 44,951 restricted stock units. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $77.79 · Expires 2031-02-08 | Direct | 11,447 |
Reported balance
After 2021-02-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-08 · Grant · Acquired 11,447 · Balance 11,447 F3: The option vests as to 25% of the shares on February 8, 2022, and the remaining 75% vests in 36 equal monthly installments at the end of each month beginning on February 28, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to 25% of the shares on February 8, 2022, and the remaining 75% vest in 36 equal monthly installments at the end of each month beginning on February 28, 2022.
F2: Includes 44,951 restricted stock units.
F3: The option vests as to 25% of the shares on February 8, 2022, and the remaining 75% vests in 36 equal monthly installments at the end of each month beginning on February 28, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 23,985 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000130 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,985 Underlying: Common Stock · 23,985 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 23,985 restricted stock units vest on 8/17/2029. F11 · derivative.expiration_date: 23,985 restricted stock units vest on 8/17/2029. Read SEC document |
| August 17, 2026 Filed Aug 19, 2026 20:47 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 14,762 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000130 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,762 Underlying: Common Stock · 14,762 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029. F10 · derivative.expiration_date: 4,921 restricted stock units vest on each of 8/17/2027 and 8/17/2028, and 4,920 restricted stock units vest on 8/17/2029. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 3,226 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,452 Underlying: Common Stock · 3,226 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F10 · derivative.expiration_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,623 Underlying: Common Stock · 2,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F7 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027. F7 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Stock Options (Right to Buy) · Derivative | 22,898 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 7 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,526 Underlying: Common Stock · 22,898 shares Expires not disclosed F5 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited. F5 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,526 performance options. The remainder of the performance options were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Disposition to issuerPerformance Restricted Stock Units · Derivative | 8,507 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 6 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,507 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 567 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · derivative · entry 5 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,507 Underlying: Common Stock · 567 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. F3 · derivative.expiration_date: On 8/15/2026, the Board of Directors authorized discretionary vesting for 567 performance RSUs. The remainder of the performance RSUs were forfeited. Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,976 | $72.40 | $143,062.40 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,943 Read SEC document |
| August 15, 2026 Filed Aug 18, 2026 21:13 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 6,416 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-26-000120 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,919 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 9,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · derivative · entry 8 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: 9,911 restricted stock units vest on 11/1/2025. F6 · derivative.expiration_date: 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 4,520 | $62.57 | $282,816.40 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,503 Read SEC document |
| November 03, 2025 Filed Nov 5, 2025 21:46 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 9,911 | $0.00 | $0.00 |
DisclosureSEC source: 0000914190-25-000029 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 24,758 | $0.00 Strike: $53.60 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 14 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,758 Underlying: Common Stock · 24,758 shares Expires 2035-08-15 F12 · derivative.exercise_date: Options to purchase 8,253 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,252 shares vest on 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 9,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,678 Underlying: Common Stock · 9,678 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. F11 · derivative.expiration_date: 3,226 restricted stock units vest on each of 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 19,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,355 Underlying: Common Stock · 19,355 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,246 Underlying: Common Stock · 2,623 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F8 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 803 | $53.60 | $43,040.80 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,112 Read SEC document |
| August 15, 2025 Filed Aug 19, 2025 21:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 2,623 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-014697 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,915 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · derivative · entry 3 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,320 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: 3,320 restricted stock units vest on 2/1/2025. F2 · derivative.expiration_date: 3,320 restricted stock units vest on 2/1/2025. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,109 | $73.55 | $81,566.95 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,292 Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 22:27 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 3,320 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001659 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,401 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionRestricted Stock Units · Derivative | 9,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,911 Underlying: Common Stock · 9,912 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F8 · derivative.exercise_date: 9,911 restricted stock units vest on 11/1/2025. F8 · derivative.expiration_date: 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 3,270 | $75.31 | $246,263.70 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · nonDerivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,081 Read SEC document |
| November 01, 2024 Filed Nov 5, 2024 21:48 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Exercise / conversionCommon Stock | 9,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-018335 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 21,204 | $0.00 Strike: $74.91 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 13 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires 2034-08-15 F12 · derivative.exercise_date: Options to purchase 5,301 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 7,869 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 12 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,869 Underlying: Common Stock · 7,869 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F11 · derivative.exercise_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. F11 · derivative.expiration_date: 2,623 restricted stock units vest on each of 8/15/2025, 8/15/2026 and 8/15/2027. Read SEC document |
| August 15, 2024 Filed Aug 19, 2024 21:29 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantPerformance Restricted Stock Units · Derivative | 15,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-015384 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,738 Underlying: Common Stock · 15,738 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F10 · derivative.exercise_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F10 · derivative.expiration_date: Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:36 UTC | BIO-TECHNE Corp TECH · Entity 3479 | Tax withholdingCommon Stock | 1,111 | $68.54 | $76,147.94 |
DisclosureSEC source: 0001062993-24-002021 · form4.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,759 F1 · balance_after: Includes 3,320 shares of restricted stock units for which the risk of forfeiture will lapse on 2/1/2025. Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 22:35 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 19,857 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020120 · form4.xml · derivative · entry 11 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,857 Underlying: Common Stock · 19,857 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F9 · derivative.exercise_date: 9,929 restricted stock units vest on 11/1/2024 and 9,928 restricted stock units vest on 11/1/2025. F9 · derivative.expiration_date: 9,929 restricted stock units vest on 11/1/2024 and 9,928 restricted stock units vest on 11/1/2025. Read SEC document |
| November 01, 2023 Filed Nov 9, 2023 21:23 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 19,823 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-020427 · form4a.xml · derivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,823 Underlying: Common Stock · 19,823 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · shares: This amendment is being filed solely to correct a typographical error in the number of restricted stock units granted. F3 · derivative.exercise_date: 9,912 restricted stock units vest on 11/1/2024 and 9,911 restricted stock units vest on 11/1/2025. F3 · derivative.expiration_date: 9,912 restricted stock units vest on 11/1/2024 and 9,911 restricted stock units vest on 11/1/2025. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 30,059 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 10 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,059 Underlying: Common Stock · 30,059 shares Expires 2030-08-15 F7 · derivative.exercise_date: Options to purchase 7,515 shares vest on each of 8/15/2024, 8/15/2025, 8/15/2027, and 7,514 shares vest on 8/15/2026. Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 22,544 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 9 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,544 Underlying: Common Stock · 22,544 shares Expires 2030-08-15 F6 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Aug 17, 2023 20:08 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 8,377 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-016695 · form4.xml · derivative · entry 8 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,377 Underlying: Common Stock · 8,377 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F6 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F6 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:15 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 24,424 | $0.00 Strike: $84.61 | $0.00 |
DisclosureSEC source: 0001062993-23-022603 · form4a.xml · derivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,424 Underlying: Common Stock · 24,424 shares Expires 2030-08-15 F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2023 Filed Dec 14, 2023 23:15 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 9,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-022603 · form4a.xml · derivative · entry 1 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,074 Underlying: Common Stock · 9,074 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F2 · derivative.exercise_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F2 · derivative.expiration_date: Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 4 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,400 Underlying: Common Stock · 7,400 shares Expires 2029-08-15 F4 · derivative.exercise_date: Options to purchase 1,850 shares vest on each of 8/15/2023, 8/15/2024, 8/51/2025 and 8/15/2026. Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Options (Right to Buy) · Derivative | 5,550 | $0.00 Strike: $378.08 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 3 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,550 Underlying: Common Stock · 5,550 shares Expires 2029-08-15 F3 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| August 15, 2022 Filed Aug 17, 2022 22:15 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 1,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-008799 · form4-08172022_030831.xml · derivative · entry 2 Geist William · CIK 0001832210 · PRESIDENT, PROTEIN SCIENCES 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,785 Underlying: Common Stock · 1,785 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 3,978 | $0.00 Strike: $401.57 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 4 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,978 Underlying: Common Stock · 3,978 shares Expires 2029-02-01 F4 · derivative.exercise_date: Options to purchase 995 shares vest on each of 2/1/2023 and 2/1/2024 and options to purchase 994 shares vest on each of 2/1/2025 and 2/1/2026. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantStock Option (right to buy) · Derivative | 2,984 | $0.00 Strike: $401.57 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 3 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,984 Underlying: Common Stock · 2,984 shares Expires 2029-02-01 F3 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 840 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · derivative · entry 2 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 840 Underlying: Common Stock · 840 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). F3 · derivative.expiration_date: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator). Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:20 UTC | BIO-TECHNE Corp TECH · Entity 3479 | GrantCommon Stock | 2,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-002402 · rdgdoc.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 F1 · balance_after: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| February 01, 2022 Filed Sep 29, 2022 20:10 UTC Amendment | BIO-TECHNE Corp TECH · Entity 3479 | GrantRestricted Stock Units · Derivative | 2,490 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-023243 · rdgdoc.xml · derivative · entry 1 Geist William · CIK 0001832210 · President, Protein Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,490 Underlying: Common Stock · 2,490 shares Expires not disclosed F1 · security: This amendment is being filed solely to move this grant of restricted stock units from Table I (where it was originally reported) to Table II. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock. F3 · derivative.exercise_date: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. F3 · derivative.expiration_date: Represents 2,490 shares of restricted stock for which the risk of forfeiture will lapse as to 830 shares on each of February 1, 2023, February 1, 2024 and February 1, 2025. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:10 UTC | Quanterix Corp QTRX · Entity 6649 | GrantStock Option (right to buy) · Derivative | 11,447 | $0.00 Strike: $77.79 | $0.00 |
DisclosureSEC source: 0001562180-21-001036 · primarydocument.xml · derivative · entry 2 Geist William · CIK 0001832210 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,447 Underlying: Common Stock · 11,447 shares Expires 2031-02-08 F3 · derivative.exercise_date: The option vests as to 25% of the shares on February 8, 2022, and the remaining 75% vests in 36 equal monthly installments at the end of each month beginning on February 28, 2022. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:10 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 4,906 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-001036 · primarydocument.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,951 F1 · shares: Represents shares of stock issuable on vesting of restricted stock units. The restricted stock units vest as to 25% of the shares on February 8, 2022, and the remaining 75% vest in 36 equal monthly installments at the end of each month beginning on February 28, 2022. F2 · balance_after: Includes 44,951 restricted stock units. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 22:26 UTC | Quanterix Corp QTRX · Entity 6649 | GrantCommon Stock | 40,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-006777 · primarydocument.xml · nonDerivative · entry 1 Geist William · CIK 0001832210 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,045 F1 · shares: Represents shares of stock issuable upon vesting of restricted stock units (RSUs). The RSUs vest as to 1/3 of the shares on November 16, 2021, with the remaining 2/3 vesting in 24 equal monthly installments at the end of each month thereafter beginning on November 30, 2021. F2 · balance_after: Includes 40,045 restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.